Company news

Alteogen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products

September 2, 2026

Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product

August 5, 2026

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

June 10, 2026

Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)

September 17, 2025

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

July 28, 2025

Decks